Sensus Healthcare Inc
NASDAQ:SRTS

Watchlist Manager
Sensus Healthcare Inc Logo
Sensus Healthcare Inc
NASDAQ:SRTS
Watchlist
Price: 8.89 USD -0.45% Market Closed
Market Cap: 145.7m USD
Have any thoughts about
Sensus Healthcare Inc?
Write Note

Sensus Healthcare Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sensus Healthcare Inc
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Sensus Healthcare Inc
NASDAQ:SRTS
Cash Equivalents
$22.6m
CAGR 3-Years
11%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Cash Equivalents
$1.7B
CAGR 3-Years
-9%
CAGR 5-Years
26%
CAGR 10-Years
-1%
Boston Scientific Corp
NYSE:BSX
Cash Equivalents
$2.5B
CAGR 3-Years
9%
CAGR 5-Years
55%
CAGR 10-Years
26%
Stryker Corp
NYSE:SYK
Cash Equivalents
$3.9B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
11%
Abbott Laboratories
NYSE:ABT
Cash Equivalents
$7B
CAGR 3-Years
-9%
CAGR 5-Years
11%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash Equivalents
$1.8B
CAGR 3-Years
32%
CAGR 5-Years
23%
CAGR 10-Years
14%
No Stocks Found

Sensus Healthcare Inc
Glance View

Market Cap
145.7m USD
Industry
Health Care

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 37 full-time employees. The company went IPO on 2016-06-03. The firm is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The firm uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The firm incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100 Plus and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100 Plus offers remote diagnostics solutions, including operation tracking.

SRTS Intrinsic Value
10.46 USD
Undervaluation 15%
Intrinsic Value
Price

See Also

What is Sensus Healthcare Inc's Cash Equivalents?
Cash Equivalents
22.6m USD

Based on the financial report for Sep 30, 2024, Sensus Healthcare Inc's Cash Equivalents amounts to 22.6m USD.

What is Sensus Healthcare Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
27%

Over the last year, the Cash Equivalents growth was 10%. The average annual Cash Equivalents growth rates for Sensus Healthcare Inc have been 11% over the past three years , 27% over the past five years .

Back to Top